This trial evaluated the safety, tolerability, pharmacodynamics, pharmacokinetics and clinical activity of AstraZeneca’s ...

Growth is driven by the increasing prevalence of neurological disorders like Alzheimer's, Parkinson's, and schizophrenia, ...

AstraZeneca secured a fast approval of lung and breast cancer drugs with usually sluggish Japanese regulators, just months after scoring similar approvals in the West. The Japanese Ministry of ...

DelveInsight’s “ Dermatomyositis Market Insight, Epidemiology, and Market Forecast – 2034 ” provides an in-depth analysis of the current landscape and future outlook of the DM market across major ...

With this quintet of FTSE 100 stocks, an investor would have portfolio exposure stretching from the Americas and Europe to ...

HSBC and Shell are the only two British companies in the top 100 of Forbes’ Global 2000, but its presence grows with 68 ...

The portfolio continues to invest in companies we believe are strong and improving and have improvement that is sustainable.

The FTSE 100 index closed up 24.59 points, 0.3%, at 8,875.22, just shy of its record closing peak of 8,884.92 posted last ...

Corvus' soquelitinib shows promise in oncology & autoimmune fields, with Phase 3 PTCL data as a key catalyst. Click here to ...

AstraZeneca is a company with a turbulent ... to grow further in 2017 when reports suggested that AZ had tried to buy Japanese company Daiichi Sankyo. Daiichi apparently declined the offer.

The FTSE 100 index closed up 24.59 points, 0.3%, at 8,875.22, just shy of its record closing peak of 8,884.92 posted last Thursday and the all-time high of 8,908.82, recorded in March. The FTSE 250 ...

New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...